SEC Form 4 · accession 0001209191-17-039505
ENDRA Life Sciences Inc. · NDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Francois Roger Michelon
Officer — Chief Executive Officer · Director
Period of report
Jun 9, 2017
Accepted (ET)
Jun 13, 2017 · 4:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681682
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $4.55 | Jun 9, 2017 | A | 31,960 | A | — | May 12, 2022 | Common Stock | 31,960 | 31,960 | D |
Explanation of responses
- F1These Stock Options become exercisable in three equal annual installments beginning on May 12, 2018.